[go: up one dir, main page]

NO992779L - OB-fusjonsproteinpreparater og fremgangsmåte - Google Patents

OB-fusjonsproteinpreparater og fremgangsmåte

Info

Publication number
NO992779L
NO992779L NO992779A NO992779A NO992779L NO 992779 L NO992779 L NO 992779L NO 992779 A NO992779 A NO 992779A NO 992779 A NO992779 A NO 992779A NO 992779 L NO992779 L NO 992779L
Authority
NO
Norway
Prior art keywords
methods
fusion protein
protein preparations
preparations
fusion
Prior art date
Application number
NO992779A
Other languages
English (en)
Other versions
NO324506B1 (no
NO992779D0 (no
Inventor
Michael Benjamin Mann
Randy Ira Hecht
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO992779D0 publication Critical patent/NO992779D0/no
Publication of NO992779L publication Critical patent/NO992779L/no
Publication of NO324506B1 publication Critical patent/NO324506B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
NO19992779A 1996-12-20 1999-06-08 OB-fusjonsprotein, nukleinsyresekvens, vektor, vertscelle, fremgangsmate for fremstilling av proteinet, farmasoytisk preparat samt anvendelse av proteinet for fremstilling av et terapeutisk preparat. NO324506B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77097396A 1996-12-20 1996-12-20
PCT/US1997/023183 WO1998028427A1 (en) 1996-12-20 1997-12-11 Ob fusion protein compositions and methods

Publications (3)

Publication Number Publication Date
NO992779D0 NO992779D0 (no) 1999-06-08
NO992779L true NO992779L (no) 1999-08-19
NO324506B1 NO324506B1 (no) 2007-11-05

Family

ID=25090296

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19992779A NO324506B1 (no) 1996-12-20 1999-06-08 OB-fusjonsprotein, nukleinsyresekvens, vektor, vertscelle, fremgangsmate for fremstilling av proteinet, farmasoytisk preparat samt anvendelse av proteinet for fremstilling av et terapeutisk preparat.
NO20071415A NO325096B1 (no) 1996-12-20 2007-03-16 OB-fusjonsprotein, nukleinsyresekvens, vektor, vertscelle, fremgangsmate for fremstilling av proteinet, farmasoytisk preparat samt anvendelse av proteinet for fremstilling av et terapeutisk preparat.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20071415A NO325096B1 (no) 1996-12-20 2007-03-16 OB-fusjonsprotein, nukleinsyresekvens, vektor, vertscelle, fremgangsmate for fremstilling av proteinet, farmasoytisk preparat samt anvendelse av proteinet for fremstilling av et terapeutisk preparat.

Country Status (25)

Country Link
EP (2) EP0954588B1 (no)
JP (2) JP4175668B2 (no)
KR (1) KR100937550B1 (no)
CN (1) CN1195858C (no)
AR (2) AR009436A1 (no)
AT (1) ATE351910T1 (no)
AU (1) AU5606098A (no)
BG (1) BG64288B1 (no)
BR (1) BR9713755A (no)
CA (1) CA2275183A1 (no)
CZ (1) CZ298203B6 (no)
DE (1) DE69737266T2 (no)
DK (1) DK0954588T3 (no)
EA (2) EA004790B1 (no)
ES (1) ES2280083T3 (no)
HU (1) HU227088B1 (no)
IL (1) IL130396A (no)
NO (2) NO324506B1 (no)
NZ (1) NZ514145A (no)
PL (1) PL194159B1 (no)
PT (1) PT954588E (no)
RS (1) RS49927B (no)
SK (1) SK287578B6 (no)
WO (1) WO1998028427A1 (no)
ZA (1) ZA9711239B (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
DE69638119D1 (de) * 1995-11-22 2010-03-11 Amgen Inc Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
ES2183351T3 (es) * 1997-04-17 2003-03-16 Amgen Inc Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
DK1037927T3 (da) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
PL202058B1 (pl) 1999-08-09 2009-05-29 Merck Patent Gmbh Wielofunkcyjne białko fuzyjne cytokin i przeciwciała
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
DE60122286T2 (de) 2000-02-11 2007-08-02 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
CA2407086A1 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
ES2288967T3 (es) 2000-06-29 2008-02-01 Merck Patent Gmbh Reforzamiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citoquina por medio del tratamiento combinado por agentes que mejoran la incorporacion de inmunocitoquina.
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
HUP0400284A3 (en) 2001-05-03 2012-09-28 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
SI2219031T1 (sl) 2001-10-22 2013-11-29 Amgen, Inc. Uporaba leptina za zdravljenje lipoatrofije pri ljudeh in metoda za ugotavljanje dovzetnosti za navedeno zdravljenje
PL206975B1 (pl) 2001-12-04 2010-10-29 Merck Patent Gmbh Immunocytokiny o modulowanej selektywności oraz ich zastosowanie
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
RU2366664C2 (ru) 2002-12-17 2009-09-10 Мерк Патент Гмбх Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
EP1773884B1 (en) 2004-08-03 2012-03-07 Innate Pharma Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286837A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and obesity related diseases
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
EA014647B1 (ru) * 2005-08-11 2010-12-30 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CN101292036B (zh) 2005-10-21 2016-04-13 弗·哈夫曼-拉罗切有限公司 用于重组表达多肽的方法
US20070179094A1 (en) 2006-01-31 2007-08-02 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
JP6174489B2 (ja) 2010-09-28 2017-08-02 アエゲリオン ファーマシューティカルズ，インコーポレイテッド 高可溶性レプチン
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
FI2764565T3 (fi) 2011-10-05 2023-04-24 Oned Mat Inc Piin nanorakenteen aktiivimateriaaleja litiumioniakkuihin ja niihin liittyviä prosesseja, koostumuksia, komponentteja ja laitteita
HUE040496T2 (hu) 2012-09-27 2019-03-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
JP6672157B2 (ja) 2013-11-26 2020-03-25 ザ チルドレンズ メディカル センター コーポレーション 肥満を処置するための化合物およびその使用方法
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
HRP20231076T1 (hr) 2016-09-12 2023-12-22 Amryt Pharmaceuticals Inc. Postupci detektiranja neutralizirajućih protutijela protiv leptina
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
CN110183530A (zh) 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH0870875A (ja) * 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
DE69638119D1 (de) * 1995-11-22 2010-03-11 Amgen Inc Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
IL124831A0 (en) * 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life

Also Published As

Publication number Publication date
HU227088B1 (en) 2010-06-28
EP0954588B1 (en) 2007-01-17
IL130396A (en) 2011-09-27
CZ298203B6 (cs) 2007-07-18
DE69737266D1 (de) 2007-03-08
EP0954588A1 (en) 1999-11-10
HUP0000302A3 (en) 2005-12-28
NO324506B1 (no) 2007-11-05
NO20071415L (no) 1999-08-19
AR009436A1 (es) 2000-04-12
EA004790B1 (ru) 2004-08-26
JP4175668B2 (ja) 2008-11-05
PL194159B1 (pl) 2007-05-31
CN1195858C (zh) 2005-04-06
EP1835030A1 (en) 2007-09-19
DK0954588T3 (da) 2007-05-14
SK287578B6 (sk) 2011-03-04
BG64288B1 (bg) 2004-08-31
EA199900575A1 (ru) 2000-02-28
NO992779D0 (no) 1999-06-08
EA004791B1 (ru) 2004-08-26
WO1998028427A1 (en) 1998-07-02
ZA9711239B (en) 1998-06-23
SK77499A3 (en) 2001-04-09
HUP0000302A2 (hu) 2000-06-28
CZ9902036A3 (cs) 2000-10-11
JP2001512417A (ja) 2001-08-21
BR9713755A (pt) 2000-02-01
AR059907A2 (es) 2008-05-07
NZ514145A (en) 2003-08-29
PT954588E (pt) 2007-03-30
KR100937550B1 (ko) 2010-01-19
ES2280083T3 (es) 2007-09-01
CN1246154A (zh) 2000-03-01
ATE351910T1 (de) 2007-02-15
JP2008289487A (ja) 2008-12-04
YU27999A (sh) 2000-10-30
JP4659068B2 (ja) 2011-03-30
IL130396A0 (en) 2000-06-01
RS49927B (sr) 2008-09-29
HK1021388A1 (en) 2000-06-09
EA200100216A1 (ru) 2001-08-27
CA2275183A1 (en) 1998-07-02
NO325096B1 (no) 2008-02-04
KR20000069617A (ko) 2000-11-25
PL334242A1 (en) 2000-02-14
BG103522A (en) 2000-03-31
AU5606098A (en) 1998-07-17
DE69737266T2 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
NO20071415L (no) OB-fusjonsproteinpreparater og fremgangsmater
IS1810B (is) Úðablöndur úr peptíðum og próteinum
NO20000700D0 (no) Interleukin-18-proteiner samt fremstilling og anvendelse derav
NO963371D0 (no) Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
DK0729951T3 (da) Naphthylforbindelser, mellemprodukter, præparater og fremgangsmåder
DK0894135T3 (da) Multivalent og multispecifikt antigenbindingsprotein
FI953705A7 (fi) Parannettu proteiinien laskostamismenetelmä
FI974429L (fi) Suspendoituja peptidi/proteiinivalmisteita
DK0894040T3 (da) Barberingssystem og fremgangsmåde
DK0729956T3 (da) Benzothi9phenforbindelser, emllemprodukter, præparater og fremgangsmåder
FI954978A7 (fi) Modifioidut proteiini- ja peptidilääkeaineet
FI970979L (fi) Muokatut ihmisen C3-proteiinit
NO980566D0 (no) Allergen-XCD32 fusjonsproteiner
DE59707298D1 (de) Desodorierende zubereitungen
NO971448D0 (no) Anti-Fas rekombinante antistoffer og DNA derfor
NO971505D0 (no) Trofinin og trofininhjelperproteiner
NO985806D0 (no) Kitinasematerialer og fremgangsmÕter
DK0826679T3 (da) Naphthylforbindelser og -præparater
NO973980D0 (no) Imiadazolderivater og medisinsk preparat
NO995062D0 (no) <Beta>-anyloidpeptid-bindende proteiner og polynuldeotider som kodes for samme
NO952763D0 (no) Ekspresjonssystemer under anvendelse av autolyserende fusjonsproteiner og et nytt reduserende polypepid
TR199701666A3 (tr) Sismanliga karsi proteinler
FI962836L (fi) Psoriasiksen vastaisia peptidejä ja menetelmiä
NO960766D0 (no) Nytt protein og fremgangsmåte for fremstilling av dette
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees